054 Treatment with ixekizumab over 60 weeks provides sustained improvements in health-related quality of life: Results from UNCOVER-1, a randomized phase 3 trial
Langley, R., Feldman, S., Paul, C., Gordon, K., Strand, V., Toth, D., Warren, R.B., Burge, R., Zhu, B., Reich, K.Volume:
136
Language:
english
Journal:
Journal of Investigative Dermatology
DOI:
10.1016/j.jid.2016.06.071
Date:
September, 2016
File:
PDF, 57 KB
english, 2016